User: Guest  Login
Title:

Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.

Document type:
Journal Article; 2
Author(s):
Deterding, Katja; Spinner, Christoph D; Schott, Eckart; Welzel, Tania M; Gerken, Guido; Klinker, Hartwig; Spengler, Ulrich; Wiegand, Johannes; Schulze Zur Wiesch, Julian; Pathil, Anita; Cornberg, Markus; Umgelter, Andreas; Zöllner, Caroline; Zeuzem, Stefan; Papkalla, Armin; Weber, Kristina; Hardtke, Svenja; von der Leyen, Heiko; Koch, Armin; von Witzendorff, Dorothee; Manns, Michael P; Wedemeyer, Heiner
Abstract:
Early treatment of acute hepatitis C virus (HCV) infection with interferon alfa is highly effective, but can be associated with frequent side-effects. We investigated the safety and efficacy of an interferon-free regimen for treatment of acute HCV infection.In this prospective, open-label, multicentre, single-arm pilot study, we enrolled adults (>=18 years) with acute HCV genotype 1 monoinfection from ten centres in Germany. Patients were given ledipasvir (90 mg) plus sofosbuvir (400 mg) as a fi...     »
Journal title abbreviation:
Lancet Infect Dis
Year:
2017
Journal volume:
17
Journal issue:
2
Pages contribution:
215-222
Language:
eng
Fulltext / DOI:
doi:10.1016/S1473-3099(16)30408-X
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/28029529
Print-ISSN:
1473-3099
TUM Institution:
II. Medizinische Klinik und Poliklinik (Gastroenterologie)
 BibTeX